Tag Archives: Valeant

June, 2018

  • 18 June

    FDA Fails to Approve Valeant’s Plaque Psoriasis Treatment

    LAVAL, Quebec, June 18, 2018 /PRNewswire/ — Ortho Dermatologics, a division of Valeant Pharmaceuticals International, Inc. (NYSE/TSX: VRX), today announced that it has received a Complete Response Letter (CRL) from the U.S. Food and Drug Administration (FDA) regarding the company’s New Drug Application (NDA) for DUOBRII™1 (halobetasol propionate and tazarotene) …

November, 2017

April, 2017

February, 2017

  • 17 February

    FDA Approves Valeant’s Siliq for Treatment of Psoriasis

    LAVAL, Quebec , Feb. 16, 2017 /PRNewswire/ — Valeant Pharmaceuticals International, Inc. (NYSE: VRX) (TSX: VRX) (“Valeant” or the “Company”) today announced that the U.S. Food and Drug Administration (FDA) has approved the Biologics License Application (BLA) for SILIQ™ (brodalumab) injection, for subcutaneous use, a monoclonal antibody that targets the …

January, 2017

November, 2016

  • 2 November

    Valeant Comments on Potential Sale of its Gastroenterology Business Unit

    LAVAL, Quebec, Nov. 1, 2016 /PRNewswire/ — Valeant Pharmaceuticals International, Inc. (NYSE: VRX and TSX: VRX) (“Valeant”) today issued the following statement regarding comments attributed to anonymous sources in a press report regarding its Gastroenterology business unit: “In accordance with its duties to shareholders and other stakeholders, management evaluates any …

July, 2016

  • 20 July

    FDA Panel Recommends Approval of Valeant’s Psoriasis Drug

    LAVAL, Quebec, July 19, 2016 /PRNewswire/ — Valeant Pharmaceuticals International, Inc. (NYSE: VRX and TSX: VRX) today announced that the Dermatologic and Ophthalmic Drugs Advisory Committee appointed by the U.S. Food and Drug Administration (FDA) has voted by a margin of 18 to 0 for the approval of brodalumab injection, 210 …